These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 10845841)

  • 1. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.
    Block GA; Port FK
    Am J Kidney Dis; 2000 Jun; 35(6):1226-37. PubMed ID: 10845841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia].
    Douthat WG; Alles A; Marinovich S; Tirado S; Peñalba A; Prudkin S
    Nefrologia; 2003; 23 Suppl 2():95-9. PubMed ID: 12778863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in hyperphosphatemia management.
    Slatopolsky E
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S297-9. PubMed ID: 12939384
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA; Hulbert-Shearon TE; Levin NW; Port FK
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.
    Román-García P; Carrillo-López N; Cannata-Andía JB
    J Ren Care; 2009 Mar; 35 Suppl 1():34-8. PubMed ID: 19222729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product.
    Moe SM; Drüeke TB
    Am J Nephrol; 2003; 23(6):369-79. PubMed ID: 14551461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues in the management of secondary hyperparathyroidism and bone disease.
    Moe SM
    Perit Dial Int; 2001; 21 Suppl 3():S241-6. PubMed ID: 11887830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperphosphatemia in dialysis patients: is there a role for focused counseling?
    Poduval RD; Wolgemuth C; Ferrell J; Hammes MS
    J Ren Nutr; 2003 Jul; 13(3):219-23. PubMed ID: 12874747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
    Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
    Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.